Send me a link:

*Text messaging rates may apply.

 Dow Up0.13% Nasdaq Down0.10%

Valeant Pharmaceuticals International, Inc. (VRX)

-NYSE
123.53 Up 0.01(0.01%) 4:03PM EDT
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
Total Revenue 5,769,605   3,480,376   2,427,450  
Cost of Revenue1,905,120  969,696  696,098  
Gross Profit 3,864,485   2,510,680   1,731,352  
Operating Expenses
Research Development156,783  79,052  65,687  
Selling General and Administrative1,510,347  810,166  568,061  
Non Recurring704,880  612,892  239,831  
Others1,901,977  928,885  557,814  
Total Operating Expenses4,273,987  2,430,995  1,431,393  
Operating Income or Loss (409,502) 79,685   299,959  
Income from Continuing Operations
Total Other Income/Expenses Net(60,634)7,683  16,567  
Earnings Before Interest And Taxes(470,136)87,368  316,526  
Interest Expense844,316  481,596  334,526  
Income Before Tax(1,314,452)(394,228)(18,000)
Income Tax Expense(450,783)(278,203)(177,559)
Minority Interest(2,473) -   -  
Net Income From Continuing Ops(931,156)(136,105)122,715  
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (866,142) (116,025) 159,559  
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (866,142) (116,025) 159,559  

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.